Cim Investment Mangement Inc. Trims Holdings in Horizon Pharma PLC (HZNP)
Cim Investment Mangement Inc. lowered its position in Horizon Pharma PLC (NASDAQ:HZNP) by 50.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,743 shares of the biopharmaceutical company’s stock after selling 10,738 shares during the quarter. Cim Investment Mangement Inc.’s holdings in Horizon Pharma were worth $210,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently added to or reduced their stakes in HZNP. First Quadrant L P CA increased its holdings in shares of Horizon Pharma by 189.1% in the third quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 4,001 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in shares of Horizon Pharma in the second quarter valued at approximately $172,000. Strs Ohio increased its holdings in shares of Horizon Pharma by 74.2% in the second quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 4,600 shares during the period. ARP Americas LP acquired a new position in shares of Horizon Pharma in the third quarter valued at approximately $229,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in shares of Horizon Pharma in the second quarter valued at approximately $234,000. 88.64% of the stock is currently owned by institutional investors and hedge funds.
In related news, Chairman Timothy P. Walbert sold 408,347 shares of the company’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the transaction, the chairman now owns 650,404 shares of the company’s stock, valued at $14,009,702.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.90% of the company’s stock.
Shares of HZNP stock opened at $20.90 on Thursday. Horizon Pharma PLC has a 1-year low of $12.55 and a 1-year high of $23.38. The firm has a market cap of $3.45 billion, a P/E ratio of 17.71, a price-to-earnings-growth ratio of 1.36 and a beta of 1.29. The company has a current ratio of 1.94, a quick ratio of 1.86 and a debt-to-equity ratio of 2.06.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.15. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The firm had revenue of $325.30 million for the quarter, compared to analyst estimates of $311.84 million. During the same quarter in the prior year, the company posted $0.26 earnings per share. Horizon Pharma’s quarterly revenue was up 19.8% on a year-over-year basis. Equities analysts predict that Horizon Pharma PLC will post 1.3 EPS for the current fiscal year.
WARNING: “Cim Investment Mangement Inc. Trims Holdings in Horizon Pharma PLC (HZNP)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2018/11/22/cim-investment-mangement-inc-trims-holdings-in-horizon-pharma-plc-hznp.html.
Horizon Pharma Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Recommended Story: Systematic Risk and Investors
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.